AAVantgarde CSO Prof. Alberto Auricchio to Present Advances in AAV Gene Therapy for Inherited Retinal Diseases at JSGCT 2026
核心洞察
AAVantgarde Bio (搜索) Founder and CSO Prof. Alberto Auricchio will speak at the 32nd Annual Meeting of the Japanese Society for Gene and Cell Therapy in Osaka, Japan, from July 23–25, 2026.
Prof. Auricchio will present at the ASGCT/ESGCT/JSGCT Joint Symposium on next-generation AAV vector technologies designed to overcome delivery limitations of conventional approaches.
AAVantgarde is a clinical-stage company with a pipeline led by programs targeting Stargardt disease (搜索) and retinitis pigmentosa (搜索) secondary to Usher syndrome type 1B (搜索), both of which currently lack approved treatments.
AAVantgarde Bio (搜索), a clinical-stage biotechnology company focused on next-generation gene therapies for inherited retinal diseases (IRDs), has announced that its Founder and Chief Scientific Officer, Prof. Alberto Auricchio, will participate in the 32nd Annual Meeting of the Japanese Society for Gene and Cell Therapy (JSGCT), taking place in Osaka, Japan, from July 23–25, 2026.
Prof. Auricchio has been invited to speak during the ASGCT/ESGCT/JSGCT Joint Symposium, a collaborative forum bringing together the American Society of Gene and Cell Therapy, the European Society of Gene and Cell Therapy, and the Japanese Society for Gene and Cell Therapy. His presentation will focus on the latest advances in AAV-based gene therapy and emerging strategies to expand the therapeutic potential of AAV vector technologies for genetic diseases.
As one of the pioneers in the development of AAV gene therapies, Prof. Auricchio has made significant contributions to the field, including the advancement of innovative vector platforms designed to overcome the delivery limitations of conventional AAV approaches. His participation at JSGCT underscores AAVantgarde's ongoing commitment to scientific excellence and international collaboration in advancing next-generation genetic medicines.
"The rapid evolution of AAV technologies continues to create new opportunities to address diseases that were previously beyond the reach of gene therapy," said Prof. Alberto Auricchio, Founder and Chief Scientific Officer of AAVantgarde. "I look forward to engaging with colleagues from Japan and around the world to discuss the latest scientific advances and the collaborative efforts that are helping bring transformative therapies closer to patients."
AAVantgarde's Pipeline and Therapeutic Focus
AAVantgarde is pioneering the development of best-in-class genetic therapies for patients with inherited retinal diseases. The company's proprietary platforms power a robust pipeline, led by programs targeting Stargardt disease (搜索) and retinitis pigmentosa (搜索) secondary to Usher syndrome type 1B (搜索) — two severe genetic retinal conditions that currently have no approved treatment options. Driven by a deep commitment to translational science and clinical excellence, AAVantgarde leverages cutting-edge genetic medicine to bring transformative treatments to patients.
The JSGCT Annual Meeting
The Japanese Society for Gene and Cell Therapy Annual Meeting brings together leading academic researchers, clinicians, and industry experts from around the world to discuss the latest developments in gene and cell therapy research, translational science, and clinical innovation. The 2026 edition, hosted in Osaka, features the joint symposium with ASGCT and ESGCT, highlighting the growing international collaboration in the gene therapy field.